

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**  
**Date of Report (Date of earliest event reported): June 1, 2017**

**Apricus Biosciences, Inc.**

(Exact name of registrant as specified in its charter)

Nevada

0-22245

87-0449967

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

11975 El Camino Real, Suite 300, San Diego, CA

92130

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (858) 222-8041

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Employee Bonuses*

On June 1, 2017, the Compensation Committee of the Board of Directors (the “Committee”) of Apricus Biosciences, Inc. (the “Company”) approved and ratified certain employee bonuses, which were intended to recognize their efforts related to the Company's sale of its ex-US Vitaros business. Special cash bonuses were issued to the following executive officers and other employees:

<u><b>Name</b></u>	<u><b>Title</b></u>	<u><b>Special Cash Bonus</b></u>
Richard Pascoe	Chief Executive Officer and Secretary	\$97,479.20
Brian Dorsey	Senior Vice President, Chief Development Officer	\$63,860.00
Neil Morton	Senior Vice President, Chief Business Officer	\$55,000.00
All other employees		\$75,000.00 (in the aggregate)

\* \* \*

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Apricus Biosciences, Inc.

Date: June 5, 2017

By: /s/ Richard W. Pascoe

Name: Richard W. Pascoe

Title: Chief Executive Officer and Secretary